Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.19 - $26.52 $65,246 - $90,168
-3,400 Reduced 29.31%
8,200 $205,000
Q2 2024

Aug 14, 2024

BUY
$15.14 - $22.99 $62,074 - $94,259
4,100 Added 54.67%
11,600 $248,000
Q1 2024

May 15, 2024

SELL
$15.35 - $18.82 $102,845 - $126,094
-6,700 Reduced 47.18%
7,500 $139,000
Q4 2023

Feb 14, 2024

SELL
$8.99 - $16.86 $33,263 - $62,382
-3,700 Reduced 20.67%
14,200 $230,000
Q3 2023

Nov 14, 2023

BUY
$10.81 - $22.96 $99,452 - $211,232
9,200 Added 105.75%
17,900 $247,000
Q2 2023

Aug 14, 2023

BUY
$17.19 - $24.34 $77,355 - $109,530
4,500 Added 107.14%
8,700 $192,000
Q1 2023

May 15, 2023

SELL
$17.67 - $26.07 $220,875 - $325,875
-12,500 Reduced 74.85%
4,200 $91,000
Q4 2022

Feb 14, 2023

BUY
$16.95 - $25.07 $283,065 - $418,669
16,700 New
16,700 $303,000

Others Institutions Holding BLFS

About BIOLIFE SOLUTIONS INC


  • Ticker BLFS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 42,684,400
  • Market Cap $1.16B
  • Description
  • BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It of...
More about BLFS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.